These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2870964)

  • 1. [Calmodulin antagonists in general practice. Evaluation of the side-effect spectrum].
    Kartnik G
    Fortschr Med Suppl; 1986; 3():18-9. PubMed ID: 2870964
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fendiline for hypodynamic coronary heart disease patients. Calmodulin antagonists--alternatives to calcium antagonism].
    Fortschr Med; 1985 Oct; 103(40):64. PubMed ID: 4065792
    [No Abstract]   [Full Text] [Related]  

  • 3. [Fendiline: clinical advantages].
    Belz GG
    Fortschr Med Suppl; 1986; 3():14-5. PubMed ID: 2870962
    [No Abstract]   [Full Text] [Related]  

  • 4. [Fendiline brings oxygen to the myocardium].
    von Bock und Polach U
    Med Klin; 1981 Sep; 76(19):541-4. PubMed ID: 7024764
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical evaluation of fendiline as a coronary drug].
    Adamska-Dyniewska H; Rosiek S; Dziekański S; Brzozowski R
    Pol Tyg Lek; 1988 Feb; 43(6):188-91. PubMed ID: 3043400
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cycloergometric evaluation of fendiline in chronic coronary insufficiency].
    Armaganijan D; Batlouni M; de Araújo JR
    Arq Bras Cardiol; 1979 Sep; 33(3):225-8. PubMed ID: 396912
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effects of fendiline in myocardial ischemia of exertion].
    Richichi I; Massacci E; Collarini L; Codega S; Venturini C; Lorenzi A
    Cardiologia; 1985 Mar; 30(3):229-33. PubMed ID: 4064073
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparative study of verapamil and fendiline in the treatment of chronic coronary insufficiency. Clinical and ergometric evaluation].
    Candau LA; Pereira LS; Lavall MA; Carvalho CR
    Arq Bras Cardiol; 1982 Aug; 39(2):135-8. PubMed ID: 6763518
    [No Abstract]   [Full Text] [Related]  

  • 9. [Role of calcium antagonists in therapy of coronary heart disease. Experimental report on the calcium antagonist fendiline, and the beta receptor blockader metoprolol].
    Ardjah H
    Med Welt; 1980 Sep; 31(37):1326-30. PubMed ID: 7432128
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effectiveness of fendiline in ischemic heart disease].
    Zochowski RJ; Rdzanek H; Sobieszczańska M; Kochmański M
    Pol Tyg Lek; 1988 Apr; 43(16):517-20, 523. PubMed ID: 3045778
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fendiline (Sensit) in the treatment of coronary disease].
    Bała T; Gajewska B; Adamska-Dyniewska H
    Wiad Lek; 1983 Apr; 36(7):525-30. PubMed ID: 6349131
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of sensit on the course of ischemic heart disease].
    Nesvetov VN; Gorshkov VA; Kuliamin VI; Buskin VD
    Sov Med; 1988; (3):57-61. PubMed ID: 3413552
    [No Abstract]   [Full Text] [Related]  

  • 13. [Fendiline hydrochloride as a therapeutic agent in chronic coronary insufficiency].
    Vichi FL
    Arq Bras Cardiol; 1980 Apr; 34(4):327-30. PubMed ID: 7002122
    [No Abstract]   [Full Text] [Related]  

  • 14. [Comparative study of the activity of fendiline and nifedipine in ischemic heart disease].
    Bertazzoni G; Migliau G; Pantani E; De Castro S; Rosini A
    Minerva Cardioangiol; 1985 Apr; 33(4):169-75. PubMed ID: 4047408
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of Sensit on central hemodynamics in patients with ischemic heart disease].
    Kliuka GR; Sinitsa KI; Okhon'ko VI; Sinitsa TN; Pilipchuk LR
    Vrach Delo; 1987 Nov; (11):19-20. PubMed ID: 3439113
    [No Abstract]   [Full Text] [Related]  

  • 16. [Type II diabetes and ischemic cardiopathy. Clinical results and possible pharmacologic interference in treatment with fendiline].
    Ferraris GM; Barberis G
    G Clin Med; 1984; 65(7-8):357-66. PubMed ID: 6500212
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of patients with ischemic heart diseases using senzit].
    Zamotaev IP; Venediktova MG; Zakharova GIu
    Klin Med (Mosk); 1988 Aug; 66(8):68-71. PubMed ID: 3193737
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects of nitroglycerin on exercise hemodynamics in patients with coronary heart disease under treatment with beta-blockers (mepindolol, oxprenolol) and a calcium-antagonist (fendiline) (author's transl)].
    Reiterer W
    Wien Med Wochenschr; 1980 Dec; 130(23):772-7. PubMed ID: 6111161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Sensit, a Ca++ antagonist, in ischaemic heart diseases.
    Antalóczy Z; Préda I
    Ther Hung; 1979; 27(2):71-6. PubMed ID: 494143
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of Sensit (fendiline) in the light of new data.
    Szám L; Tardos L
    Ther Hung; 1987; 35(1):19-22. PubMed ID: 3326203
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.